M Kochanek1,2, A Shimabukuro-Vornhagen3,4, K Rüß3, G Beutel4,5, C Lueck4,5, M Kiehl4,6, R Schneider7, F Kroschinsky4,7, T Liebregts4,8, S Kluge9, P Schellongowski4,10, M von Bergwelt-Baildon4,11, B Böll3,4. 1. Klinik I für Innere Medizin, Klinikum der Universität zu Köln (AöR), Kerpener Str. 62, 50937, Köln, Deutschland. matthias.kochanek@uk-koeln.de. 2. "Intensive Care in Hematologic and Oncologic Patients (iCHOP)", . matthias.kochanek@uk-koeln.de. 3. Klinik I für Innere Medizin, Klinikum der Universität zu Köln (AöR), Kerpener Str. 62, 50937, Köln, Deutschland. 4. "Intensive Care in Hematologic and Oncologic Patients (iCHOP)". 5. Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation, Medizinische Hochschule Hannover, Hannover, Deutschland. 6. Medizinische Klinik I, Brandenburger Stammzelltransplantationszentrum, Klinikum Frankfurt (Oder), Frankfurt (Oder), Deutschland. 7. Medizinische Klinik I, Uniklinikum Dresden, Dresden, Deutschland. 8. Westdeutsches Tumorzentrum, Klinik für Knochenmarktransplantation, Universitätsklinikum Essen, Universität Duisburg Essen, Essen, Deutschland. 9. Klinik für Intensivmedizin, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland. 10. Universitätsklinik für Innere Medizin I, Medizinische Universität Wien, Wien, Österreich. 11. Medizinische Klinik und Poliklinik III, Klinikum der Universität München, Campus Großhadern, München, Deutschland.
Abstract
INTRODUCTION: Cancer is one of the leading causes of death worldwide. Due to increasing comorbidities, age and aggressive chemotherapy, care of cancer patients in intensive care units (ICUs) is more and more necessary. So far, little is known about the care structure of cancer patients in German ICUs. The aim of this work is to collect and evaluate the prevalence and care data of cancer patients on two reference dates. METHODS: German ICUs were invited to participate in a 2-day, prospective, multicenter point prevalence study in ICU cancer patients. Participation in the study was voluntary and the study was not funded. An ethics vote was obtained to conduct the study. The data were anonymously entered into an eCRF (electronic case report form) by the participating centers. Identification of the patients is therefore not possible. RESULTS: About one in four patients on the ICU/IMC ward had hematological-oncological (HO) disease (n = 316/1319, 24%). The proportion depended significantly on the number of beds in each hospital. The most frequent reasons for admission to the ICU/IMC station were postoperative monitoring (n = 83/221, 37.6%), respiratory instability (n = 79/221, 35.7%), circulatory instability (n = 52/221; 23.5%) and the severe infection with sepsis (n = 47/221; 21.3%). In all, 66.5% (n = 147/221) of the patients had a solid tumor and 21.7% (n = 48/221) had hematological cancer, 78.3% (n = 173/221) of the documented cancer patients received "full-code" intensive management, while 42.5% (n = 94/221) of the HO patients were ventilated and 40.7% (n = 90/221) required catecholamines. The median (mean; IQR) SAPS II score was 35 (37.79, IQR = 24-48) and the median (mean, IQR) TISS score was 10 (13.26, IQR = 10-15). Through the analysis and evaluation of the data available in the context of the prevalence study, it was possible for the first time to determine the Germany-wide cross-center prevalence and care situation of hematological cancer patients in intensive care and intermediate care stations. About one in four patients on German ICUs and IMC wards have a major or minor cancer diagnosis (n = 316/1319 = 24%). Care management is complex in this patient population and requires close interdisciplinary collaboration.
INTRODUCTION:Cancer is one of the leading causes of death worldwide. Due to increasing comorbidities, age and aggressive chemotherapy, care of cancerpatients in intensive care units (ICUs) is more and more necessary. So far, little is known about the care structure of cancerpatients in German ICUs. The aim of this work is to collect and evaluate the prevalence and care data of cancerpatients on two reference dates. METHODS: German ICUs were invited to participate in a 2-day, prospective, multicenter point prevalence study in ICU cancerpatients. Participation in the study was voluntary and the study was not funded. An ethics vote was obtained to conduct the study. The data were anonymously entered into an eCRF (electronic case report form) by the participating centers. Identification of the patients is therefore not possible. RESULTS: About one in four patients on the ICU/IMC ward had hematological-oncological (HO) disease (n = 316/1319, 24%). The proportion depended significantly on the number of beds in each hospital. The most frequent reasons for admission to the ICU/IMC station were postoperative monitoring (n = 83/221, 37.6%), respiratory instability (n = 79/221, 35.7%), circulatory instability (n = 52/221; 23.5%) and the severe infection with sepsis (n = 47/221; 21.3%). In all, 66.5% (n = 147/221) of the patients had a solid tumor and 21.7% (n = 48/221) had hematological cancer, 78.3% (n = 173/221) of the documented cancerpatients received "full-code" intensive management, while 42.5% (n = 94/221) of the HO patients were ventilated and 40.7% (n = 90/221) required catecholamines. The median (mean; IQR) SAPS II score was 35 (37.79, IQR = 24-48) and the median (mean, IQR) TISS score was 10 (13.26, IQR = 10-15). Through the analysis and evaluation of the data available in the context of the prevalence study, it was possible for the first time to determine the Germany-wide cross-center prevalence and care situation of hematological cancerpatients in intensive care and intermediate care stations. About one in four patients on German ICUs and IMC wards have a major or minor cancer diagnosis (n = 316/1319 = 24%). Care management is complex in this patient population and requires close interdisciplinary collaboration.
Entities:
Keywords:
Cancer; Hematology; Intensive care unit; Intermediate care station; Oncology; Prevalence
Authors: Matthias Kochanek; Jan Kochanek; Boris Böll; Dennis A Eichenauer; Gernot Beutel; Hendrik Bracht; Stephan Braune; Florian Eisner; Sigrun Friesecke; Ulf Günther; Gottfried Heinz; Michael Hallek; Christian Karagiannidis; Stefan Kluge; Klaus Kogelmann; Pia Lebiedz; Philipp M Lepper; Tobias Liebregts; Catherina Lueck; Ralf M Muellenbach; Matthias Hansen; Christian Putensen; Peter Schellongowski; Jens-Christian Schewe; Kathrin Schumann-Stoiber; Frederik Seiler; Peter Spieth; Steffen Weber-Carstens; Daniel Brodie; Elie Azoulay; Alexander Shimabukuro-Vornhagen Journal: Intensive Care Med Date: 2022-02-10 Impact factor: 17.440